北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo
作者: Tan, Qiang1,2; Li, Jing2; Yin, Han-wei3; Wang, Li-hui2; Tang, Wan-chen2; Zhao, Fang2; Liu, Xin-min1; Zeng, Hui-hui2,4
关键词: Ethaselen ; Thioredoxin reductase inhibitor ; Cisplatin ; Non-small cell lung cancer ; Combination chemotherapy ; Synergistic effect
刊名: INVESTIGATIONAL NEW DRUGS
发表日期: 2010-06-01
DOI: 10.1007/s10637-009-9235-7
卷: 28, 期:3, 页:205-215
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Pharmacology & Pharmacy
研究领域[WOS]: Oncology ; Pharmacology & Pharmacy
关键词[WOS]: LUNG-CANCER CELLS ; MAMMALIAN THIOREDOXIN ; POSSIBLE INVOLVEMENT ; CYCLE ARREST ; APOPTOSIS ; CARCINOMA ; DESIGN ; GROWTH ; LINES ; CIS-DIAMMINEDICHLOROPLATINUM(II)
英文摘要:

Ethaselen (1, 2-[bis (1, 2-Benzisoselenazolone-3 (2H) -ketone)] ethane, BBSKE), as a novel organoselenium compound targeting thioredoxin reductase (TrxR), has been reported to inhibit tumor growth and TrxR activity in several human tumor cell lines. It has now entered Phase I clinical trails. Here we report the effects of ethaselen and cisplatin (cis-diamminedichloroplatinum II, DDP) combination therapy (ethaselen 36 mg/kg, i.g., o.d. x 10 d and cisplatin 1 mg/kg, i.p., single at day 0) on human A549-grafted nude mouse model (female, BALB/c nude mouse, n = 5, treatment after tumor volume reached 100 mm(3)). Compared to single drug administration (either ethaselen: 36 mg/kg, i.g., o.d. x 10 d or cisplatin: 1.0 mg/kg, i.p., single at day 0), the combination therapy showed significantly reduced tumor size (presumably due to a synergistic effect) and no obvious toxic damage (both in terms of body weight maintenance and liver/kidney damage). These results will be significant in the development of novel anti-tumoral therapeutic strategies directed to non-small cell lung cancer (NSCLC).

语种: 英语
所属项目编号: 30472036
项目资助者: National Natural Science Foundation of China
WOS记录号: WOS:000276430200001
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/50438
Appears in Collections:北京大学第一临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Hosp 1, Beijing 100034, Peoples R China
2.Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
3.Peking Univ, Coll Life Sci, Beijing 100075, Peoples R China
4.Peking Univ, Hlth Sci Ctr, Sch Pharmaceut Sci, Beijing 100191, Peoples R China

Recommended Citation:
Tan, Qiang,Li, Jing,Yin, Han-wei,et al. Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo[J]. INVESTIGATIONAL NEW DRUGS,2010,28(3):205-215.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Tan, Qiang]'s Articles
[Li, Jing]'s Articles
[Yin, Han-wei]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Tan, Qiang]‘s Articles
[Li, Jing]‘s Articles
[Yin, Han-wei]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace